|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis:results from the 52-week,PhaseⅢChina-centric study,MEASURE 5显示文摘Background:Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis(AS)through 5 years in pivotal Phase III studies.Here,we present efficacy and safety results(52-week)of secukinumab in patients with AS from the MEASURE 5 study.Methods:MEASURE 5 was a 52-week,Phase III,China-centric study.Eligible patients were randomly assigned(2:1)to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks(q4w).All placebo patients switched to secukinumab 150 mg q4w starting at Week 16.Primary endpoint was Assessments of SpondyloArthritis international Society(ASAS)20 at Week 16.Randomization was stratified by region(China vs.non-China).Results:Of 458 patients(secukinumab 150 mg,N=305;placebo,N=153)randomized,327(71.4%)were from China and 131(28.6%)were not from China.Of these,97.7%and 97.4%patients completed Week 16 and 91.1%and 95.3%(placebo-secukinumab)patients completed Week 52 of treatment.The primary endpoint was met;secukinumab significantly improved ASAS20 response at Week 16 vs.placebo(58.4%vs.36.6%;P<0.0001);corresponding rate in the Chinese population was 56.0%vs.38.5%(P<0.01).All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16;responses were maintained with a trend toward increased efficacy from Week 16 to 52.No new or unexpected safety signals were reported up to Week 52.Conclusions:Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS.Secukinumab was well tolerated and the safety profile was consistent with previous reports.Efficacy and safety results were comparable between the overall and Chinese populations. | Feng Huang Fei Sun Wei-Guo Wan Li-Jun Wu Ling-Li Dong Xiao Zhang Tae-Hwan Kim Raj Sengupta Ladislav Senolt Yi Wang Hao-Min Qiu Brian Porter Sibylle Haemmerle | 2020 | Chinese Medical Journal2020，，21： | 2 |
| 2 | Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis显示文摘 | Senolt L Polansk~i M Filkov~i M | 2010 | Ann Rheum Dis2010，69，7： | 1 |
| 3 | Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis显示文摘 | Senolt L Polanska M Filkova M | 2010 | Ann Rheum Dis2010，69，7： | 1 |
| 4 | Vaspin and omentin newadipokines differentially regulated at the site of inflammation in rheu-matoid arthritis 显示文摘 | Senolt L Polanska M Filkovd M | 2010 | Ann Rheum Dis2010，69，7： | 1 |
| 5 | 难治性类风湿关节炎的临床特点:一项国际问卷调查研究显示文摘目的尽管按照目前欧洲抗风湿联盟(EULAR)的推荐对类风湿关节炎(rheumatoid arthritis,RA)患者进行治疗,难治性RA患者的临床症状却仍然没有得到完全控制,目前EULAR指南主要关注的是RA的早期治疗和药物治疗。本研究的目的在于分析难治性RA患者的临床特点,以及在患者管理中需要探索然而现有EULAR指南并未涉及的问题。方法对多个国家的风湿科医生进行问卷调查,分析难治性RA的临床特点。问卷包括多选题以及开放性问题,从开放性问题的回答中发现需要进一步阐明的问题以及现有EULAR指南需要增加的内容。结果410名受访者完成了调查问卷,关于难治性RA的特点:50%受访者认为基于28个关节评估的疾病活动评分(disease activity score assessing 28 joints,DAS28)>3.2或存在疾病活动的征象;42%受访者认为疲劳是其特点;48%认为至少两种传统合成改变病情抗风湿药(DMARDs)以及使用至少两种生物制剂或靶向合成DMARDs治疗失败;89%认为糖皮质激素不能减量到5 mg/天或泼尼松不能减量到10 mg/天或同等剂量的其他激素。另外,现有EULAR指南中应增加合并症和关节外表现的干预以及多种药物联合治疗等重要内容。结论目前风湿科医生对难治性RA的定义有很大争议。难治性RA患者的很多重要问题目前EULAR指南中均没有涉及。 | Nadia MT Roodenrijs Maria J H de Hair Marlies C van der Goes Johannes WG Jacobs Paco MJ Welsing Désirée van der Heijde Daniel Aletaha Maxime Dougados Kimme L Hyrich Iain B McInnes Ulf Mueller-Ladner Ladislav Senolt Zoltan Szekanecz Jacob Mvan Laar Nagy Gyorgy 黄艳荣(译) 张卓莉(审校) | 2019 | 英国医学杂志中文版2019，22，2： | 1 |
| 6 | The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy显示文摘 | Senolt L Krytffkovt Oj Hulejov Hj | 2011 | Cytokine2011，55，1： | 1 |
| 7 | Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?显示文摘 | Senolt L Grassi W Szodoray P | 2014 | BMC Med2014，12，： | 1 |
| 8 | Resistin is abun-dantly present in rheumatoid arthritis synovial tissue,synovial flu-id,and elevated serum resistin reflects disease activity显示文摘 | SENOLT L HOUSA D VERNEROVA Z | 2007 | AnnRheum Dis2007，66，： | 1 |
| 9 | Vaspin andomentin:new adipokines differentially regulated at the site of in-flammation in rheumatoid arthritis显示文摘 | SENOLT L POLANSKA M FILKOVA M | 2010 | Ann Rheum Dis2010，699，7： | 1 |
| 10 | Increased adiponectin is negatively linked to the local inflammstory process in patients with rheumatoid arthritis显示文摘 | Senolt L Pavelka K Housa D | 2006 | Cytokine2006，35，56： | 1 |
| 11 | Vaspin and omentin:new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis显示文摘 | Senolt L Polanská M Filková M | 2010 | Ann Rheum Dis2010，69，7： | 1 |
| 12 | S100A4 is expressed at site of invasion in reumatoid arthritis synovium and modulates pro-duction of matrix metalloproteinases显示文摘 | Senolt L Grigorian M Lukanidin E | 2006 | Ann Rheum Dis2006，65，12： | 1 |
| 13 | Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis显示文摘 | Senolt L Hulejova H Krystufkova O | 2012 | Ann Rheum Dis2012，71，1： | 1 |
| 14 | The level of serum vis- fatin(PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy显示文摘 | Senolt L Krystufkova O Hulejova H | 2011 | Cytokine2011，55，1： | 1 |
| 15 | Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis显示文摘 | Senolt L Pavelka K Housa D | 2006 | Cytokine2006，35，56： | 1 |
| 16 | Serum hyaluronic acid as a poten- tial marker with a predictive value for further radiographic progression of handosteoaxlhritis显示文摘 | FilkovO M Senolt L Braun M | 2009 | Osteoarthrifis Cartilage2009，17，12： | 1 |
| 17 | Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis 显示文摘 | Filkova M Aradi B Senolt L | 2014 | Ann Rheum Dis2014，73，10： | 1 |
| 18 | Association of cir-culating miR-223 and miR-16 with disease activity in patientswith early rheumatoid arthritis显示文摘 | FILKOV M ARADI B SENOLT L | 2014 | Ann Rheum Dis2014，73，10： | 1 |
| 19 | Increased serum concentrationof immune cell derived microparticles in polymyositis/dermatomyositis显示文摘 | Baka Z Senolt L Vencovsky J | 2010 | Immunol Lett2010，128，2： | 1 |
| 20 | Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis显示文摘 | Filkovd M Aradi B Senolt L | 2014 | Ann Rheum Dis2014，73，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员